Editorials

When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes

Andalusian Initiative for Advanced Therapies, Servicio Andaluz de Salud, Junta de Andalucía, Sevilla, Spain
Cell Therapy Unit, IMIBIC, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
Division of Hematology, University of Toronto, Cell Therapy Program, Princess Margaret Hospital, Toronto, Canada
Vol. 98 No. 3 (2013): March, 2013 https://doi.org/10.3324/haematol.2013.086231